Niagen Bioscience (NASDAQ:NAGE) Shares Gap Up - Time to Buy?

Niagen Bioscience Inc (NASDAQ:NAGE - Get Free Report)'s share price gapped up before the market opened on Friday . The stock had previously closed at $11.51, but opened at $11.94. Niagen Bioscience shares last traded at $11.94, with a volume of 146,099 shares traded.Get Niagen Bioscience alerts:Wall Street Analysts Forecast GrowthSeparately, Canaccord Genuity Group began coverage on Niagen Bioscience in a research note on Tuesday, May 27th. They set a "buy" rating and a $13.00 price target on the stock.Read Our Latest Research Report on NAGENiagen Bioscience Stock Up 6.7%The firm has a market capitalization of $967.30 million, a price-to-earnings ratio of 72.24 and a beta of 1.94. The firm has a 50-day moving average price of $8.45. Niagen Bioscience Company Profile (Get Free Report)Niagen Bioscience, Inc is a global bioscience company, which engages in acquiring, developing, and commercializing proprietary-based ingredient technologies. It is pioneering research on nicotinamide adenine dinucleotide (NAD+). The company's patent portfolio includes Nicotinamide Riboside (NR) and other NAD+ precursors, which are commercialized as the flagship ingredient Niagen.Featured StoriesFive stocks we like better than Niagen BioscienceMost active stocks: Dollar volume vs share volumeAre NVIDIA's Ethernet Wins Signs of Hope or Horror for Arista?3 Must-Buy Warren Buffett Stocks for Volatile TimesBroadcom Slides on Solid Earnings, AI Outlook Still Strong3 Natural Gas Stocks That Offer Great Dividend YieldsThe Market’s Silent Warning: What Bonds and Gold RevealThis instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.Should You Invest $1,000 in Niagen Bioscience Right Now?Before you consider Niagen Bioscience, you'll want to hear this.MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Niagen Bioscience wasn't on the list.While Niagen Bioscience currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.View The Five Stocks Here